Corcept Therapeutics Inc
CORT40.830USD
+2.470+6.44%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.29BMarket Cap
39.97P/E TTM
More Details of Corcept Therapeutics Inc Company
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Corcept Therapeutics Inc Info
Ticker SymbolCORT
Company nameCorcept Therapeutics Inc
IPO dateApr 15, 2004
CEOBelanoff (Joseph K)
Number of employees500
Security typeOrdinary Share
Fiscal year-endApr 15
Address101 Redwood Shores Parkway
CityREDWOOD CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94065
Phone16506888803
Websitehttps://www.corcept.com/
Ticker SymbolCORT
IPO dateApr 15, 2004
CEOBelanoff (Joseph K)
Company Executives of Corcept Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.56K
+238.00%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.52K
+246.00%
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
1.24K
--
Mr. George Leonard Baker, Jr.
Mr. George Leonard Baker, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
--
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+129142.00%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+64824.00%
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
101.05K
+65016.00%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
97.87K
+275.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.00%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
Other
62.45%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
10.39%
The Vanguard Group, Inc.
9.00%
Ingalls & Snyder LLC (Asset Management)
7.32%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.05%
Other
62.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
40.65%
Investment Advisor/Hedge Fund
22.93%
Individual Investor
11.70%
Hedge Fund
7.47%
Pension Fund
1.37%
Sovereign Wealth Fund
0.96%
Research Firm
0.74%
Bank and Trust
0.45%
Family Office
0.13%
Other
13.60%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
796
79.55M
83.53%
-3.32K
2025Q3
810
79.55M
83.49%
-543.84K
2025Q2
778
80.03M
86.89%
-4.55M
2025Q1
736
84.99M
89.94%
-9.90M
2024Q4
668
86.02M
93.22%
-3.95M
2024Q3
614
90.10M
96.25%
-1.26M
2024Q2
578
91.29M
99.95%
-4.43M
2024Q1
572
95.57M
89.61%
+2.81M
2023Q4
546
86.50M
88.14%
+1.82M
2023Q3
531
84.62M
88.02%
+2.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
10.93M
10.39%
-380.74K
-3.37%
Sep 30, 2025
The Vanguard Group, Inc.
9.51M
9.05%
-144.25K
-1.49%
Sep 30, 2025
Ingalls & Snyder LLC (Asset Management)
7.70M
7.32%
-24.94K
-0.32%
Sep 30, 2025
Renaissance Technologies LLC
6.09M
5.79%
-177.06K
-2.83%
Sep 30, 2025
Baker (George Leonard Jr.)
5.31M
5.05%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.87M
3.68%
+329.00
+0.01%
Sep 30, 2025
Belanoff (Joseph K)
2.98M
2.83%
--
--
Dec 24, 2025
State Street Investment Management (US)
2.97M
2.82%
+2.81K
+0.09%
Sep 30, 2025
Wilson (James N)
2.35M
2.23%
+129.14K
+5.82%
Apr 17, 2025
Fidelity Management & Research Company LLC
2.15M
2.04%
+789.13K
+58.16%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P SmallCap Health Care ETF
4.22%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Invesco Pharmaceuticals ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.67%
iShares U.S. Pharmaceuticals ETF
2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.48%
Formidable ETF
2.47%
Alger Russell Innovation ETF
2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
1.73%
Fidelity Stocks for Inflation ETF
1.52%
View more
Invesco S&P SmallCap Health Care ETF
Proportion4.22%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.34%
Invesco Pharmaceuticals ETF
Proportion2.82%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.67%
iShares U.S. Pharmaceuticals ETF
Proportion2.55%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.48%
Formidable ETF
Proportion2.47%
Alger Russell Innovation ETF
Proportion2.09%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.73%
Fidelity Stocks for Inflation ETF
Proportion1.52%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
